Clinical Trial Update: Study of Recombinant Human Serum Albumin/Interferon alpha2b Fusion Protein in Hepatitis B Patient [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial of recombinant human serum albumin/interferon alpha2b fusion protein for Hepatitis B has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Recombinant human serum albumin/interferon alpha2b fusion protein

Snippet

Sponsor: Tianjin SinoBiotech Ltd. | Conditions: Hepatitis B Virus | Phase 1, Phase 2 | Status: COMPLETED